First phase viral kinetic parameters as predictors of treatment response and their influence on the second phase viral decline

Journal of Viral Hepatitis

Volumn 9, Issue 5, 2002, Pages 340-345

  Layden, Jennifer E ^a   Layden, Thomas J ^a,e   Reddy, K Rajender ^b   Levy Drummer, Rachel S ^c   Poulakos, Jennifer ^d   Neumann, Avidan U ^c  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b UNIVERSITY OF MIAMI   (United States)

^c BAR ILAN UNIVERSITY   (Israel)

^d AMGEN INC   (United States)

^e 840 S Wood/Digestive and Liver Diseases   (United States)

Author keywords

Hepatitis C; IFN; Mathematical model; Prediction; Sustained viral response (SVR); Viral kinetics

Indexed keywords

CONSENSUS INTERFERON; RECOMBINANT ALPHA2B INTERFERON; VIRUS RNA;

ACCURACY; ARTICLE; BLOOD ANALYSIS; CALCULATION; CELL LOSS; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG EFFICACY; DRUG RESPONSE; FISHER EXACT TEST; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IMMUNE RESPONSE; IMMUNOTHERAPY; KINETICS; LINEAR REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MATHEMATICAL MODEL; PREDICTION; PRIORITY JOURNAL; TREATMENT OUTCOME; VIRUS DETECTION; VIRUS LOAD; VIRUS REPLICATION; VIRUS TYPING;

ANTIVIRAL AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; HEPACIVIRUS; HEPATITIS C; HUMANS; INTERFERONS; KINETICS; MATHEMATICAL COMPUTING; MODELS, STATISTICAL; RETROSPECTIVE STUDIES; VIRAL LOAD;

EID: 0036380991     PISSN: 13520504     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2893.2002.00377.x     Document Type: Article

References (24)

1. Hoofnagle JH, Tralka TS. The National Institutes of Health Consensus Development Conference: Management of Hepatitis C. Hepatology 1997; 26(3) (Suppl. 1): 785-825.
2. McHutchison JG, Gordon SC, Schiff ER et al. Interferon alpha-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998; 339: 1485-1492.
3. Poynard T, Marcellin P, Lee SS et al. Interferon alpha 2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha-2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT) Lancet 1998; 352: 1426-1432.
4. Karino Y, Toyota J, Sugawara M et al. Early loss of serum hepatitis C virus RNA can predict a sustained response to interferon therapy in patients with chronic hepatitis C. AJG 1997; 301: 61-65.
5. Zeuzem S, Lee J, Franke A et al. Quantification of the initial decline of serum hepatitis C virus RNA and response to interferon alfa. Hepatology 1998; 27: 1149-1154.
6. Orito E, Mizokami M, Suzuki K et al. Loss of serum HCV RNA at week 4 of interferon alpha therapy is associated with more favorable long-term response in patients with chronic hepatitis C. J Med Virol 1995; 46: 109-115.
7. Brouwer J, Hansen B, Niesters H, Schalm S. Early prediction of response in interferon monotherapy and in interferon-ribavirin combination therapy for chronic hepatitis C: HCV RNA at 4 weeks versus ALT. J Hepatol 1999; 30: 192-198.
8. Gavier B, Martinez-Gonzalex M, Riezu-Boj J et al. Viremia after one month of interferon therapy predicts treatment outcome in patients with chronic hepatitis C. Gastroenterology 1997; 113: 1647-1653.
9. Civiera M, Prieto J. Early predictors of response to treatment in patients with chronic hepatitis C. J Hepatol 1999; 31: 237-243.
10. Izopet J, Payen J, Alric L et al. Baseline level and early suppression of serum HCV RNA for predicting sustained complete response to alpha-interferon therapy. J Med Virol 1998; 54: 86-91.
11. Lee W, Reddy R, Tong M et al. Early hepatitis C virus-RNA responses predict interferon treatment outcomes in chronic hepatitis C. Hepatology 1998; 28: 1411-1416.
12. Zeuzem S, Schmidt JM, Lee JH, Ruster B, Roth WK. Effect of interferon alpha on the dynamics of hepatitis C virus turnover in vivo. Hepatology 1996; 23: 366-371.
13. Lam NP, Neumann AU, Gretch DR, Wiley TE, Perelson AS, Layden TJ. Dose-Dependent acute clearance of hepatitis C genotype 1 virus with interferon alpha. Hepatology 1997; 26: 226-231.
14. Neumann AU, Lam NP, Dahari H et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha-therapy. Science 1998; 282: 103-107.
15. Zeuzem S, Herrmann E, Lee JH et al. Viral kinetics in patients with chronic hepatitis C treated with standard or peginterferon alpha2a. Gastroenterology 2001; 120: 1438-1447.
16. Neumann AU, Lam NP, Dahari H et al. Differences in viral dynamics between genotypes 1 and 2 of hepatitis C virus. JID 2000; 182: 28-35.
17. Neumann AU, Layden TJ, Reddy R, Levi-Drummer R, Poulakos J. The 2nd phase slope of HCV decline is highly predictive of sustained virologic response following CIFN treatment for chronic hepatitis C and is determined by genotype but not dose. Hepatology 2000; 32(4) (Part 2): 356A.
18. Neumann AU, Zeuman S, Brunda MJ, Hoffmann JH. Rapid viral response to treatment with pegylated (40KDA) interferon alpha-2A (Pegasys) is strongly predictive of a sustained virologic response in patients with chronic hepatitis C (CHC). Hepatology 2000; 32 (4) (2): 318A.
19. Layden TJ, Layden JE, Reddy KR, Levy-Drummer RS, Poulakos J, Neumann AU. Induction therapy with consensus interferon does not improve sustained virologic response in chronic hepatitis C. J Viral Hep 2002; 9: 334-339.
20. Jessner W, Gschwantler M, Steindl-Munda P et al. Primary Interferon resistance and treatment response in chronic hepatitis C infection: a pilot study. Lancet 2001; 358: 1241-1242.
21. Jessner W, Stauber R, Gschwantler M et al. Viral dynamics on pegylated (PEG 40KD) IFN alfa-2a differs from standard IFN in patients infected with HCV genotype 1. Abstract. 8th International Symposium on Hepatitis C and Related Viruses. Paris, France, 2-5 September 2001.
22. Vogel W, Brunner H, Stauber R, Werner L, Gschwantler M, Stadler B. Measurement of viral IFN sensitivity in patients with chronic hepatitis C prospective, randomized, open label phase III clinical trial. Hepatology 2001 32(4) (Part 2): 337A.
23. Boni C, Penna A, Ogg GS et al. Lamuvidine treatment can overcome cytotoxic T-cell hyporesponsiveness in chronic hepatitis B. new perspectives for immune therapy. Hepatology 2001; 33: 963-971.
24. Boni C, Bertoletti A, Penna A et al. Lamuvidine treatment can restore T cell responsiveness in chronic hepatitis B. J Clin Invest 1998; 102: 968-975.